RxDoctor Payments Data

Bashar Samman, MD

Interventional Cardiology · Port Huron, MINPI 1558322743

Payments from drug & device makers

$1,413in general payments, 2019–2025

Across 69 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$608
  • Boston Scientific$145
  • Amgen$91
  • Preventice Services, LLC$82
  • AstraZeneca$68
  • Johnson & Johnson$60
  • plus $360 from 15 others

What the payments were for

  • Food & beverage$1,413100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,413 in reported general payments places this provider in the 10th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$573,068
Medicare patients
1,294
Services billed
6,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban819$970,713
XareltoRivaroxaban416$494,758
JardianceEmpagliflozin190$225,051
EntrestoSacubitril/Valsartan81$121,292
FarxigaDapagliflozin Propanediol82$97,558
Repatha SureclickEvolocumab42$57,270
Atorvastatin Calcium1,615$26,390
MultaqDronedarone Hcl18$19,854
BrilintaTicagrelor16$16,708
Ezetimibe590$16,178
Repatha SyringeEvolocumab19$15,343
Metoprolol Succinate485$9,448
Isosorbide Mononitrate ErIsosorbide Mononitrate513$8,842
Metoprolol Tartrate1,042$8,491
Losartan Potassium537$7,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$970,713819 claims
Johnson & JohnsonXarelto$60$494,758416 claims
Boehringer IngelheimJardiance$48$225,051190 claims
NovartisEntresto$608$121,29281 claims
AstraZenecaFarxiga, Brilinta$68$114,26598 claims
Sanofi-aventis U.S. LLCMultaq$18$19,85418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Port Huron

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →